Loading patent…
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsMarco Davila, Brian Betts
Estimating the term…
Disclosed are compositions and methods for preventing graft versus host disease (GVHD) in subjects receiving donor cells. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to suppress alloreactive donor cells. Therefore, also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the disclosed regulatory T cells engineered to express the disclosed CARs. Also disclosed is a method of preventing rejection of off-the-shelf therapeutic immune effector cells, such as CAR-T cells, in a subject that involves administering to the subject an effective amount of a regulatory T cell genetically modified with a disclosed CD83-specific CAR.
A method of suppressing alloreactive donor cells in a subject receiving transplant donor cells, the method comprising administering to the subject an effective amount of a first immune effector cell genetically modified to express a first chimeric antigen receptor (CAR) polypeptide, comprising a CD83 antigen binding domain, a transmembrane domain, an intracellular signaling domain, and a co-stimulatory signaling region, thereby suppressing alloreactive donor cells in the subject.
A method for treating a subject, comprising co-administering to the subject a therapeutic amount of a first non-autologous, non-HLA-matched immune effector cell genetically modified to express a first chimeric antigen receptor (CAR) polypeptide and a second non-autologous, non-HLA-matched immune effector cell genetically modified to express a second CAR polypeptide comprising a CD83 antigen binding domain.
Dependencies are inferred from the claim text.